Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel

This publication has 10 references indexed in Scilit:

• Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol
  Contraception, 2006
• Combination Estrogen–Progestin Oral Contraceptives
  New England Journal of Medicine, 2003
• Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives
  The Lancet, 2001
• Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis
  BMJ, 2000
• Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
  The Lancet, 1995
• Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
  The Lancet, 1995
• Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
  The Lancet, 1995
• Oral contraceptive use and venous thromboembolism: absence of an effect of smoking.
  BMJ, 1977
• THROMBOEMBOLISM AND ORAL CONTRACEPTIVERS: AN EPIDEMIOLOGIC CASE-CONTROL STUDY12
  American Journal of Epidemiology, 1969
• Investigation of relation between use of oral contraceptives and thromboembolic disease.
  BMJ, 1968